Linezolid

Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB

Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

Clinical Study on the Early Bactericidal Activity of Contezolid Against Mycobacterium Abscessus Disease

Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis

Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB

Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort

A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis

Finding the Optimal Regimen for Mycobacterium Abscessus Treatment

TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB

Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort

Phase 2 Trial Assessing TBAJ876 or Bedaquiline, with Pretomanid and Linezolid in Adults with Drug-sensitive Pulmonary Tuberculosis

Evaluating Newly Approved Drugs for Multidrug-resistant TB

Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)

Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis

Treatment Shortening of MDR-TB Using Existing and New Drugs

Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS

MRX-I Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection